{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:33:59Z","timestamp":1788654839454,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015722","name":"Centre Hospitalier Universitaire de Clermont-Ferrand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cgh.2025.07.044","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T22:09:17Z","timestamp":1755554957000},"page":"1141-1150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Comparison of the Effectiveness of Tofacitinib and Ustekinumab in Patients With Ulcerative Colitis: The TORUS Study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-409X","authenticated-orcid":false,"given":"Anthony","family":"Buisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Serrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Altwegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Guilmoteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bouguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nachury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucine","family":"Vuitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Treton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Caillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.07.044_bib1","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ibd.22839","article-title":"Ulcerative colitis as a progressive disease: the forgotten evidence","volume":"18","author":"Torres","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.07.044_bib2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.07.044_bib3","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.07.044_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cgh.2025.07.044_bib5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.044_bib6","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/apt.16605","article-title":"Loss of response to anti-TNF\u03b1 agents depends on treatment duration in patients with inflammatory bowel disease","volume":"54","author":"Schultheiss","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.07.044_bib7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.07.044_bib8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.07.044_bib9","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.07.044_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.07.044_bib11","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/jpm14101066","article-title":"Efficacy of second-line biological therapies in moderate to severe ulcerative colitis patients with prior failure of anti-tumor necrosis factor therapy: a multi-center study","volume":"14","author":"Na","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.cgh.2025.07.044_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12876-022-02225-w","article-title":"Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn\u2019s disease in patients with prior failure of anti-tumour necrosis factor treatment","volume":"22","author":"Hyun","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cgh.2025.07.044_bib13","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ibd\/izab097","article-title":"Real-world comparison of tofacitinib vs ustekinumab among bio-exposed patients with ulcerative colitis: a propensity score analysis","volume":"27","author":"Dalal","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.07.044_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ueg2.12492","article-title":"Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: a multicenter international study","volume":"12","author":"Allocca","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.cgh.2025.07.044_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ibd\/izad087","article-title":"1-Year comparative effectiveness of tofacitinib vs ustekinumab for patients with ulcerative colitis and prior antitumor necrosis factor failure","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.07.044_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/apt.17570","article-title":"Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: a propensity-matched cohort study","volume":"58","author":"Kochhar","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.07.044_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.cgh.2025.07.044_bib18","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","volume":"14","author":"Amiot","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.07.044_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ecco-jcc\/jjx143","article-title":"Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis","volume":"12","author":"Engel","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.07.044_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ibd\/izac119","article-title":"Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study","volume":"29","author":"Buisson","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.07.044_bib21","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/ecco-jcc\/jjae063","article-title":"Real-world comparison of the effectiveness between ustekinumab and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"18","author":"Fumery","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.07.044_bib22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.17305","article-title":"Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"57","author":"Buisson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.07.044_bib23","first-page":"60","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology 2024;167"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525007001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525007001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:18:18Z","timestamp":1774023498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525007001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1542356525007001"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.07.044","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Comparison of the Effectiveness of Tofacitinib and Ustekinumab in Patients With Ulcerative Colitis: The TORUS Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.07.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the AGA Institute","name":"copyright","label":"Copyright"}]}}